Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine the pharmacokinetics of BTDS following same-site patch reapplication after rest intervals.
| Condition | Intervention | Phase |
|---|---|---|
|
Healthy |
Drug: Buprenorphine transdermal patch |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Pharmacokinetics Study Intervention Model: Parallel Assignment Masking: Open Label |
| Official Title: | A Parallel Open-Label Study to Examine Plasma Concentrations of Buprenorphine Following Reapplication of 10-mg Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods in Healthy Subjects |
- Period 1: AUC0-3d [ Time Frame: 0 to 3 days (72 hours) ] [ Designated as safety issue: No ]Period 1 was the first application of BTDS 10: To determine the minimum application site rest periods that ensured that the reapplication of BTDS to the same site in the deltoid region did not result in increased absorption of the drug as measured by AUC0-3d [The area under the plasma concentration-time course profile from time = 0 (dosing) through day 3 (to 72 hours)].
- Period 2: AUC0-3d. [ Time Frame: 0 to 3 days ] [ Designated as safety issue: No ]
Period 2 was the second application of BTDS 10: To determine the minimum application site rest periods that ensured that the reapplication of BTDS to the same site in the deltoid region did not result in increased absorption of the drug as measured by AUC0-3d.
AUC0-3d - The area under the plasma concentration-time course profile from time = 0 (dosing) through day 3 (to 72 hours).
- Period 1: Cmax0-3d [ Time Frame: 0 to 3 days ] [ Designated as safety issue: No ]
Period 1 was the first application of BTDS 10: To determine the minimum application site rest periods that ensured that the reapplication of BTDS to the same site in the deltoid region did not result in increased absorption of the drug as measured by Cmax0-3d.
Cmax0-3d - The maximum observed concentration taken directly from the plasma concentration-time course profile from time = 0 (dosing) through day 3 (to 72 hours). This was considered an index of maximum (peak) exposure to the study drug.
- Period 2: Cmax0-3d [ Time Frame: 0 to 3 days ] [ Designated as safety issue: No ]
Period 2 was the second application of BTDS 10: To determine the minimum application site rest periods that ensured that the reapplication of BTDS to the same site in the deltoid region did not result in increased absorption of the drug as measured by Cmax0-3d.
Cmax0-3d (pg/mL) - The maximum observed concentration taken directly from the plasma concentration-time course profile from time = 0 (dosing) through day 3 (to 72 hours). This was considered an index of maximum (peak) exposure to the study drug.
- Period 1: AUC0-7d. [ Time Frame: 0 to 7 days ] [ Designated as safety issue: No ]
Period 1 was the first application of BTDS 10: The time for absorption to return to normal measured by AUC0-7d.
AUC0-7d - The area under the plasma concentration-time course profile from time = 0 (dosing) to BTDS removal.
- Period 2: AUC0-7d [ Time Frame: 0 to 7 days ] [ Designated as safety issue: No ]
Period 2 was the second application of BTDS 10: The time for absorption to return to normal measured by AUC0-7d.
AUC0-7d - The area under the plasma concentration-time course profile from time = 0 (dosing) to BTDS removal.
- Period 1: Cmax0-7 [ Time Frame: 0 to 7 days ] [ Designated as safety issue: No ]
Period 1 was the first application of BTDS 10: The time for absorption to return to normal measured by Cmax0-7.
Cmax0-7d - The maximum observed concentration taken directly from the plasma concentration-time course profile.
- Period 2: Cmax0-7d [ Time Frame: 0 to 7 days ] [ Designated as safety issue: No ]
Period 2 was the second application of BTDS 10: The time for absorption to return to normal measured by Cmax0-7d.
Cmax0-7d - The maximum observed concentration taken directly from the plasma concentration-time course profile.
- Period 1: Tmax0-7d. [ Time Frame: 0 to 7days ] [ Designated as safety issue: No ]
Period 1 was the first application of BTDS 10: The time for absorption to return to normal measured by Tmax0-7d.
Tmax0-7d - The time from dosing to the maximum observed concentration was taken directly from the plasma concentration-time course profile. If the maximum plasma concentration was observed at 2 or more consecutive time points, the earliest time point was used for Tmax.
- Period 2: Tmax0-7d. [ Time Frame: 0 to 7 days ] [ Designated as safety issue: No ]
Period 2 was the second application of BTDS 10: The time for absorption to return to normal measured by Tmax0-7d.
Tmax0-7d - The time from dosing to the maximum observed concentration was taken directly from the plasma concentration-time course profile. If the maximum plasma concentration was observed at 2 or more consecutive time points, the earliest time point was used for Tmax.
| Enrollment: | 70 |
| Study Start Date: | November 2000 |
| Study Completion Date: | March 2001 |
| Primary Completion Date: | March 2001 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: No Rest
BTDS 10 with no application site rest period prior to application of second BTDS
|
Drug: Buprenorphine transdermal patch
Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
Other Name: Butrans™
|
|
Experimental: 7-Day Rest
BTDS 10 with 7-day rest period prior to application of second BTDS
|
Drug: Buprenorphine transdermal patch
Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
Other Name: Butrans™
|
|
Experimental: 14-Day Rest
BTDS 10 with 14-day rest period prior to application of second BTDS
|
Drug: Buprenorphine transdermal patch
Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
Other Name: Butrans™
|
|
Experimental: 21-Day Rest
BTDS 10 with 21-day rest period prior to application of second BTDS
|
Drug: Buprenorphine transdermal patch
Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
Other Name: Butrans™
|
|
Experimental: 28-Day Rest
BTDS 10 with 28-day rest period prior to application of second BTDS
|
Drug: Buprenorphine transdermal patch
Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
Other Name: Butrans™
|
Detailed Description:
The purpose of this study is to determine the minimum application site rest period that ensures that reapplication of BTDS 10 to the same site in the deltoid region does not result in increased absorption of drug in normal healthy subjects.
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria Include:
- Males and females 18 to 45 years of age, inclusive.
- Weight of 60 to 100 kilograms (kg) [132-220 pounds (lb)] and within 15% of optimum for height and body frame.
- In good health, evidenced by a lack of significantly abnormal findings on medical history, physical examination, clinical laboratory tests, vital signs, and electrocardiogram (ECG).
- Willing to discontinue and abstain from any medications, including vitamins or mineral supplements, throughout the study.
- Willing to follow dietary restrictions, including abstention from caffeine and xanthine-containing beverages for the duration of the study.
- Did not smoke or chew tobacco for at least 45 days prior to administration of study drugs, and agree not to use tobacco products during the study
Exclusion Criteria Include:
- A history of hypersensitivity to opioid or psychotropic drugs.
- A history of recurrent seizures or syncope.
- Any medical or surgical conditions which might interfere with transdermal absorption, distribution, metabolism, or excretion of drugs.
- Any other significant active medical illness such as: history or presence of liver disease or liver injury that is indicated by an abnormal liver function profile such as aspartate transaminase (AST), alanine transaminase (ALT), or serum bilirubin; history or presence of impaired renal function that is indicated by abnormal creatinine or blood urea nitrogen (BUN) values or abnormal urinary constituents (eg, albuminuria); history of neutropenia (absolute neutrophil count [ANC] <1000/mm3 or thrombocytopenia (platelet <150,000/mm3).
- Positive results of urine drug screen or urine cotinine (consistent with active smoking).
- A history of substance or alcohol abuse within the past 5 years.
- Females who are nursing.
- Females who are pregnant as confirmed by a positive serum human chorionic gonadotropin (bHCG) test.
Other protocol-specific exclusion/inclusion criteria may apply.
Contacts and Locations More Information
Additional Information:
No publications provided
| Responsible Party: | Purdue Pharma LP |
| ClinicalTrials.gov Identifier: | NCT01259102 History of Changes |
| Other Study ID Numbers: | BUP1002 |
| Study First Received: | December 10, 2010 |
| Results First Received: | January 13, 2011 |
| Last Updated: | August 27, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Purdue Pharma LP:
|
Healthy subjects Opioid Transdermal |
Additional relevant MeSH terms:
|
Buprenorphine Analgesics, Opioid Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Central Nervous System Depressants Narcotic Antagonists Narcotics |
ClinicalTrials.gov processed this record on May 23, 2013